Leah Lynn Frye

USPTO Granted Patents = 16 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 6.0

ph-index = 7

Forward Citations = 125(Granted Patents)

Location History:

Patterson, NY (US) (2002 - 2007)
Portland, OR (US) (2002 - 2017)

Company Filing History:

6 out of 276

Boehringer Ingelheim Pharmaceuticals, Inc.

Bikam Pharmaceuticals Inc.

Years Active: 2002-2017

Loading Chart...

16 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9757370 - Opsin-binding ligands, compositions and methods of use (2017-09-12),

2. 9708326 - Inhibitors of bruton's tyrosine kinase (2017-07-18),

3. 9580416 - Inhibitors of Bruton's tyrosine kinase (2017-02-28),

4. 9499464 - Opsin-binding ligands, compositions and methods of use (2016-11-22),

5. 9469642 - Purinone compounds as kinase inhibitors (2016-10-18),

6. 9402826 - Neuronal pain pathway modulators (2016-08-02),

7. 9353063 - Opsin-binding ligands, compositions and methods of use (2016-05-31),

8. 9340554 - IRAK inhibitors and uses thereof (2016-05-17),

9. 8846742 - Neuronal pain pathway modulators (2014-09-30),

10. 8703941 - IRAK inhibitors and uses thereof (2014-04-22),

11. 7279472 - Compounds useful as reversible inhibitors of cysteine proteases (2007-10-09),

12. 7265132 - Compounds useful as reversible inhibitors of cysteine proteases (2007-09-04),

13. 6420364 - Compound useful as reversible inhibitors of cysteine proteases (2002-07-16),

14. 6414153 - 1-phenylpydrrolidin-2-ones and -thiones and 1-(4-pyridyl)pydrrolidin-2-ones and -thiones which are useful in the treatment of inflammatory disease (2002-07-02),

15. 6395897 - Nitrile compounds useful as reversible inhibitors of &num;9 cathepsin 5 (2002-05-28),

Title: Innovations and Contributions of Leah Lynn Frye in Ophthalmology and Autoimmunity

Introduction: Leah Lynn Frye, based in Portland, OR, has made significant strides in the field of biomedical research, particularly in ophthalmology and autoimmune conditions. With a remarkable portfolio consisting of 16 patents, Leah has contributed to developing compounds with potential therapeutic applications that address pressing health issues.

Latest Patents: Leah’s latest patents showcase her expertise in creating novel compounds and methods aimed at treating various medical conditions. One notable patent is focused on "Opsin-binding ligands, compositions and methods of use." This invention targets ophthalmic conditions linked to the accumulation of toxic visual cycle products in the eye, such as dry adult macular degeneration. The patent discusses formulations of these compounds, potentially enhancing treatment options for patients suffering from these debilitating conditions. Furthermore, her work encompasses methods for synthesizing these agents, underscoring her commitment to advancing medical science.

Another significant patent involves "Inhibitors of Bruton's Tyrosine Kinase," which are crucial for treating autoimmune diseases and various cancers, including lymphoma. This patent outlines compounds that form irreversible and reversible covalent bonds with Bruton's tyrosine kinase, offering innovative strategies for managing complex health issues. The therapeutic methods described within this patent promise new avenues for combination treatments alongside other therapeutic agents.

Career Highlights: Leah has a distinguished career, having been associated with leading pharmaceutical companies such as Boehringer Ingelheim Pharmaceuticals, Inc. and Pharmacyclics, Inc. Her experience in these organizations has equipped her with the skills and knowledge to drive impactful research, leading to her extensive patent portfolio.

Collaborations: Throughout her career, Leah has collaborated with prominent colleagues, including Jeremy Robert Greenwood and Yancey David Ward. These partnerships have contributed to the refinement and development of her innovative ideas, leading to successful patent applications and advancements in their respective fields.

Conclusion: Leah Lynn Frye stands out as a leading inventor in biomedical research, with a focus on ophthalmic and autoimmune treatments. Her contributions through 16 patents reflect her dedication to improving patient outcomes and addressing complex health challenges. As her work continues, it will be exciting to see how her innovations will shape the future of medicine.

This text is generated by artificial intelligence and may not be accurate.